Stay updated with breaking news from Agonist Use. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The study reveals a significant increase in the usage of GLP-1 receptor agonists, particularly Ozempic and Trulicity, for weight management and Type 2 diabetes in the U.S. from 2014 to 2022. Amidst rapid growth and shortages, the paper calls for evidence-based decision-making to ensure stable medication supply and effective treatment.
Yang Xu, Director of Medical Affairs for Respiratory & Immunology at AstraZeneca UK, explores whether the UK over-relies on SABA inhalers, and how we can do better to improve asthma care and treatment.
Taiwan: A recent population-based cohort study published in Clinical Gastroenterology and Hepatology has revealed multiple benefits of glucagon-like peptide-1 receptor agonist (GLP-1 RA) in patients...
Search jobs 22-Jan-2021 Global GLP-1 Receptor Agonist Market Projected to Witness a Measurable Downturn; COVID-19 Outbreak Remains a Threat to Growth in the Near Future GLP-1 Receptor Agonist Market: Global Industry Analysis 2015-2019 & Opportunity Assessment 2020-2030 A recent market study published by Future Market Insights (FMI) on the GLP-1 Receptor Agonist Market offers global industry analysis for 2015-2019 & opportunity assessment for 2020-2030. The report consists of a comprehensive assessment of the most important market dynamics. On...